Tests a pump-driving device for children with severe heart failure awaiting transplant
Tests a device that drives a heart pump in children with heart failure awaiting transplant.
Key facts
- Who runs it
- Berlin Heart, Inc
- Where
- Ann Arbor, Aurora, Austin, Boston, Charlotte, Chicago, Cincinnati, Gainesville, Houston, Los Angeles, Milwaukee, New York, Palo Alto, Philadelphia, Salt Lake City, St Louis, and Washington D.C., United StatesSee the 17 sites
- Trial code
- Registry title
- EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
- Status
- Enrolling by invitation
- People taking part
- 40 people, planned
- Started
- 14 Nov 2022
- Expected to end
- Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- EXCOR Active Driving System for Pediatric VAD
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with severe heart failure who are waiting for a heart transplant and need a heart pump (EXCOR Pediatric VAD) as support until then.
- Age
- Up to 21 years.
- Sex
- All sexes.
- Disease stage
- Severe heart failure of the left side or both sides of the heart. They are candidates for a heart transplant and need circulatory support.
Main reasons for not taking part
- Cannot tolerate blood-thinning (anticoagulation) treatment
- Aortic valve leak worse than moderate that cannot be repaired at implantation
- Needs the aortic valve surgically closed
- Needs the device as a total artificial heart
- Does not give written consent (patient or legal representative)
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patient meets all indications as specified in the current version of the Instructions for Use (IFU) of the EXCOR® Pediatric VAD system as shown below:; "EXCOR is intended to provide mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients. Pediatric patients with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using EXCOR."
- Patient and/or legal representative has signed the study informed consent form
Who cannot take part
- Patient has any contraindication as specified in the current version of the IFU of the EXCOR® Pediatric VAD system as shown below:; "Patients unable to tolerate systemic anticoagulation therapy should not be implanted with EXCOR components; Magnetic Resonance Imaging (MRI) is contraindicated in patients after being implanted with EXCOR; Patients with aortic valve regurgitation that is more than moderate that cannot be re- paired at the time of implantation should not be implanted with EXCOR. If repair of the aortic valve regurgitation requires surgical closure of the aortic valve, EXCOR should not be implanted. EXCOR is not intended to be used as a total artificial heart and should not be used in this configuration."
- Females of childbearing age who are not on contraceptives or surgically sterile or pregnant
- Patient and/or legal representative has not given written consent to participate in the study (non-consent)
Where in United States
- CS Mott Children's HospitalAnn Arbor, United StatesEnrolling by invitation
- Children's Hospital ColoradoAurora, United StatesEnrolling by invitation
- Dell Children's Medical CenterAustin, United StatesEnrolling by invitation
- Boston Children's HospitalBoston, United StatesEnrolling by invitation
- Levine Children's HospitalCharlotte, United StatesEnrolling by invitation
- Ann & Robert H. Lurie Children's HospitalChicago, United StatesEnrolling by invitation
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesEnrolling by invitation
- University of Florida - ShandsGainesville, United StatesEnrolling by invitation
- Texas Children's HospitalHouston, United StatesEnrolling by invitation
- Children's Hospital of Los AngelesLos Angeles, United StatesEnrolling by invitation
- Children's Hospital WisconsinMilwaukee, United StatesEnrolling by invitation
- Columbia University Medical CenterNew York, United StatesEnrolling by invitation
- Lucile Packard Children's Hospital - StanfordPalo Alto, United StatesEnrolling by invitation
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
- Primary Children's HospitalSalt Lake City, United StatesEnrolling by invitation
- St. Louis Children's HospitalSt Louis, United StatesEnrolling by invitation
- Children's NationalWashington D.C., United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the device performance and monitor the safety and effectiveness of the Berlin Heart EXCOR Active Driving System while being used with the approved EXCOR Pediatric Ventricular Assist Device.
Read full original descriptionShow less
EXCOR Active Driving System is intended for use with the approved EXCOR Pediatric VAD.
The EXCOR Pediatric VAD is intended to provide mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients. Pediatric candidates with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR Pediatric.
EXCOR Active is intended for use in a clinical setting. EXCOR Active can be used in any kind of hospital unit (e.g. OR, ICU, intermediate care unit or general care unit). The driving unit may be moved between clinical units using the caddy or baby buggy; however, a patient must always be accompanied by a person trained in the use of the manual pump and emergency procedures during transport in the event of an emergency.
The driving unit can be transported during operation.
The 2 groups in the trial
- Active Driver Primary ArmTreatment being tested
Up to 40 patients whom receive the Active Driver from implant.
Treatment: EXCOR Active Driving System for Pediatric VAD
- IKUS ComparatorNo study treatment, for comparison
All patients whom receive the (FDA approved) IKUS Driver from implant and are entered into the ACTION Registry.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
- Plain-language title
- Tests a pump-driving device for children with severe heart failure awaiting transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 October 2026